MedTrace Logo

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

NCT05219500 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2026-04-03

No results posted yet for this study

Summary

The treatment regimen will consist of 4 doses of FPI-2265

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

FPI-2265

Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225

Sponsors & Collaborators

  • Fusion Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Keith Barnett · Fusion Pharmaceuticals Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-16
Primary Completion
2025-05-30
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05219500 on ClinicalTrials.gov